A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
The purpose of this study is to find out whether the combination of glofitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle Cell Lymphoma
Mantle Cell Lymphoma|MCL
DRUG: Glofitamab|DRUG: Obinutuzumab|DRUG: Lenalidomide
Proportion of participants who successfully receive glofitamab, Treatment feasibility defined as the proportion of participants who successfully receive glofitamab during cycles 1-3 without any dose delays of glofitamab for greater than 7 days, 1 year
The purpose of this study is to find out whether the combination of glofitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle Cell Lymphoma